VC firms
Founded in 2008 and inspired by a biblical worldview, Eventide strives to serve individuals, financial advisors, and institutions by providing high-performance investments that create compelling value for the global common good.
Overview
Investment Stage
Series D
Portfolio 1
| Date | Name | Website | Total Raised | Location |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 9
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 15, 2026 | AdvanCell Closes US $315M in Series D Funding | AdvanCell, a Boston, MA- and Brisbane, Australia-based clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, raised US $315M Series D in funding. The round was led by Ally Bridge Group and Alpha Wave, al... |
| Aug 22, 2024 | PreciseDx's $20.7 Million Boost: A New Dawn for AI in Cancer Diagnostics | In the world of oncology, every second counts. PreciseDx, a trailblazer in cancer diagnostics, has just secured a significant lifeline. The company raised $20.7 million in Series B funding, bringing its total funding to $31.5 million. This ... |
| Aug 22, 2024 | Eventide Announces Hire of I-hung Shih, PhD as Managing Director and Portfolio Manager | BOSTON, Aug. 22, 2024 /PRNewswire/ -- Eventide Asset Management is pleased to announce the hire of I-hung Shih, PhD as a Managing Director of Eventide Ventures and as Portfolio Manager of the Eventide Healthcare & Life Sciences Fund sta... |
| Aug 21, 2024 | PreciseDx Raises $20.7M for AI-Powered Cancer Risk Assessments | What You Should Know: – PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, Ge... |
| Feb 27, 2024 | Freenome scores $254M to advance its cancer-detection blood tests | The San Francisco company readies to reveal its first clinical study results in the near term When it comes to cancer, spotting it early can make a big difference on treatment options and survival. Commonly a progressive disease, certain un... |
| Feb 20, 2024 | Freenome's $254M Boost for Early Cancer Detection | Freenome, a biotech company in San Francisco, just secured a massive $254M in funding to advance their blood-based cancer detection tests. The investment, led by Roche and backed by a slew of other big names, will propel Freenome's mission ... |
| Feb 15, 2024 | Freenome Raises $254M to Accelerate Early Cancer Detection Platform | What You Should Know: – Freenome, a leader in blood-based early cancer detection, has raised $254M in a new funding round, fueled by its innovative multiomics platform and promising pipeline of tests. The funding was led by Roche with parti... |
| Aug 4, 2023 | What Gordon Moore’s Legacy Can Teach Us About Where We Put Our Money | Robin John serves as a Founding Member and Chief Executive Officer of Eventide Asset Management. |
Reviews 0
FAQ about Eventide
How many startups has Eventide invested in?
Eventide has 1 portfolio company on Parsers VC.
What has the press written about Eventide?
Parsers VC has collected 9 articles mentioning Eventide, among them “AdvanCell Closes US $315M in Series D Funding” (Jul 15, 2026) and “PreciseDx's $20.7 Million Boost: A New Dawn for AI in Cancer Diagnostics” (Aug 22, 2024).
Is Eventide still active?
Yes, Eventide is active; its latest activity on Parsers VC dates from Jul 16, 2026.